Kodiak Sciences Inc.
Clinical-stage biopharma developing therapeutics for chronic retinal diseases.
KOD | US
Overview
Corporate Details
- ISIN(s):
- US50015M1099
- LEI:
- Country:
- United States of America
- Address:
- 1200 PAGE MILL RD, 94304 PALO ALTO
- Website:
- https://kodiak.com/
- Sector:
- Manufacturing
Description
Kodiak Sciences Inc. is a clinical-stage biopharmaceutical company focused on researching, developing, and commercializing therapeutics for chronic, high-prevalence retinal diseases. The company's mission is to address the leading causes of blindness, such as wet age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion. Its core technology is the proprietary Antibody Biopolymer Conjugate Drug (ABCD) Platform, which is designed to create long-acting biologics with enhanced durability, potentially reducing treatment frequency for patients. Kodiak's late-stage clinical pipeline includes its lead candidate, tarcocimab tedromer, an anti-VEGF therapy, as well as other candidates targeting retinal vascular diseases and macular edema.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Kodiak Sciences Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Kodiak Sciences Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Kodiak Sciences Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
